HALOZYME THERAPEUTICS, INC. - Common Stock (HALO)

Q4 2018 13F Holders as of 31 Dec 2018

Type / Class
Equity / Common Stock
Shares outstanding
123,650,000
Total 13F shares
117,718,613
Share change
-2,218,778
Total reported value
$1,722,184,556
Put/Call ratio
59%
Price per share
$14.63
Number of holders
182
Value change
-$44,165,796
Number of buys
82
Number of sells
86

Institutional Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q4 2018

As of 31 Dec 2018, HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) was held by 182 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 117,718,613 shares. The largest 10 holders included Third Security, LLC, Vanguard Group Inc, BlackRock Inc., IRIDIAN ASSET MANAGEMENT LLC/CT, BB BIOTECH AG, Invesco Ltd., JPMORGAN CHASE & CO, STATE STREET CORP, PICTET ASSET MANAGEMENT LTD, and Thrivent Financial for Lutherans. This page lists 184 institutional shareholders reporting positions in this security for the Q4 2018 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.